{"title":"Furaprevir。HCV NS3/4A蛋白酶抑制剂治疗慢性丙型肝炎病毒感染道感染","authors":"P. Ghosh, V. Nehra, Z. Temesgen","doi":"10.1358/dof.2022.47.8.3440035","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Furaprevir. HCV NS3/4A protease inhibitor, Treatment of chronic hepatitis C virus infection tract infection\",\"authors\":\"P. Ghosh, V. Nehra, Z. Temesgen\",\"doi\":\"10.1358/dof.2022.47.8.3440035\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":11366,\"journal\":{\"name\":\"Drugs of The Future\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drugs of The Future\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1358/dof.2022.47.8.3440035\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs of The Future","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1358/dof.2022.47.8.3440035","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
期刊介绍:
A leading international, peer-reviewed biomedical research journal publishing articles on topics emerging from the confluence of fields including chemistry, biology, pharmacology, genomics and medicine, and addressed to scientists and researchers involved in drug design, discovery and development, target identification and validation, and the preclinical and clinical development of treatments for common as well as rare and neglected diseases and conditions.
The journal publishes monographs containing comprehensive product information on new compounds in development, including synthesis, preclinical pharmacology, pharmacokinetics and metabolism, safety, clinical studies and drug interactions, as well as review articles on a variety of topics, congress and meeting reports.